A third round of software enhancements has been made to the iLab System 1.3, an ultrasound imaging system designed to strengthen physician confidence in the diagnosis and intervention of percutaneous coronary intervention (PCI) and increase workflow efficiency.

The Artida is reportedly the first ultrasound system with the ability to track and display myocardial motion and 3D volumes in 3D images. Two and 3D wall motion tracking features allow the user to obtain angle-independent, quantitative and regional information about myocardial contraction.

February 8, 2008 - CryoLife Inc. received 510(k) clearance from the FDA for its CryoValve SG pulmonary human heart valve processed with the company’s proprietary SynerGraft technology, providing a valve replacement option for children born with heart defects or for replacement surgery.

February 8, 2008 - Emageon received first place in the “Best in KLAS” Top 20 Report for the Cardiology PACS nomination for its HeartSuite solution, marking important end-user and market recognition for the product.

The Best in KLAS Top 20 Report is an annual year-end report card of vendor performance. The report provides a summary of performance data collected over the past 13 months and ranks the top overall vendors, as well as leaders in each market segment.

February 8, 2008 - The FDA granted Volcano Corp. 510(k) clearance for its s5-Revo and s5-FFR (fractional flow reserve) options, allowing physicians access phased Array IVUS, Rotational IVUS and integrated FFR on the same integrated IVUS platform.

February 7, 2008 - Volcano Corp. said the FDA cleared the s5-Revo and s5-FFR (fractional flow reserve) options, enabling rotational intravascular ultrasound (IVUS) and FFR to operate on the same integrated Volcano s5 Imaging System as Volcano’s previous line of phased array IVUS catheters and functionality.

February 8, 2008 – CryoLife Inc. said it received FDA 510(k) clearance for its CryoValve SG pulmonary human heart valve processed with the company's SynerGraft technology, which is designed to remove allogeneic donor cells and cellular remnants from the valve without compromising the integrity of the underlying collagen matrix.

CryoLife Inc.'s CryoValve SG pulmonary human heart valve is processed with the company’s proprietary SynerGraft technology, providing a valve replacement option for children born with heart defects or for replacement surgery.

Emageon's HeartSuite offers cardiovascular information management, hemodynamic monitoring, advanced visualization and content management. Emageon’s architecture combines HeartSuite with radiology and other medical specialties designed to offer a comprehensive patient–centric view of the visual medical record. One suite of integrated, enterprise cardiology tools includes:

February 8, 2008 - The FDA granted Volcano Corp. 510(k) clearance for its s5-Revo and s5-FFR (fractional flow reserve) options, allowing physicians access phased Array IVUS, Rotational IVUS and integrated FFR on the same integrated IVUS platform.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now